Lasofoxifene is a next-generation non-steroidal SERM that differs from other SERMs based on its binding affinity, which is similar to 17β-estradiol, and strong preclinical data in ER-mutated breast cancer models which are resistant to AIs30. Here, ESR1 is linked to breast cancer.